Key points are not available for this paper at this time.
Numerous considerations and controversies attend the question of which endpoints to use in venous thromboembolism prophylaxis trials. In this paper, a rationale is presented for a new approach that simplifies certain aspects of endpoint detection in deep vein thrombosis and pulmonary embolism trials, and complicates others. The goal of this approach is to use reliably ascertainable endpoints that are clinically relevant and most probably predictive of clinical efficacy, in order to optimally inform the drug development process.
Bruce L. Davidson (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: